These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. ST2 pathogenetic profile in ambulatory heart failure patients. Bayes-Genis A; Januzzi JL; Gaggin HK; de Antonio M; Motiwala SR; Zamora E; Galán A; Domingo M; Urrutia A; Lupón J J Card Fail; 2015 Apr; 21(4):355-61. PubMed ID: 25451702 [TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531 [TBL] [Abstract][Full Text] [Related]
9. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. Pascual-Figal DA; Ordoñez-Llanos J; Tornel PL; Vázquez R; Puig T; Valdés M; Cinca J; de Luna AB; Bayes-Genis A; J Am Coll Cardiol; 2009 Dec; 54(23):2174-9. PubMed ID: 19942089 [TBL] [Abstract][Full Text] [Related]
10. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Lupón J; de Antonio M; Galán A; Vila J; Zamora E; Urrutia A; Bayes-Genis A Mayo Clin Proc; 2013 Mar; 88(3):234-43. PubMed ID: 23384388 [TBL] [Abstract][Full Text] [Related]